Literature DB >> 22297558

Detection of tPA-induced hyperfibrinolysis in whole blood by RapidTEG, KaolinTEG, and functional fibrinogenTEG in healthy individuals.

Gustav Folmer Genét1, Sisse Rye Ostrowski, Anne Marie Sørensen, Pär Ingemar Johansson.   

Abstract

BACKGROUND: Rapid identification of clinically relevant coagulopathies in, acute coagulopathy of trauma shock (ACOTS) has led to the development of faster point-of-care viscoelastic whole-blood-based tests like rapid thrombelastography (RapidTEG). The sensitivity of RapidTEG to detect hyperfibrinolysis, as compared to standard KaolinTEG, is unknown. To investigate this, the ability of RapidTEG, KaolinTEG, and functional fibrinogenTEG (FFTEG) to detect tPA-induced (tissue plasminogen activator) lysis in whole blood from healthy individuals was investigated. Our hypothesis was that the initial powerful clot formation in the RapidTEG assay would reduce the sensitivity as compared to the normally used KaolinTEG assay. We also evaluated the FFTEG assay.
METHODS: In vitro comparison of the sensitivity of RapidTEG, KaolinTEG, and FFTEG to 1.8 nmol/L tPA in citrated whole blood (299 ± 23 ng/mL plasma) induced hyperfibrinolysis in 10 healthy individuals and duplicate titration of the tPA whole blood (WB) concentration from 0.09 to 7.2 nmol/L (14-1144 ng/mL plasma) in 1 healthy donor.
RESULTS: At 1.8 nmol/L tPA, KaolinTEG, RapidTEG, and FFTEG all detected fibrinolysis but with different sensitivities. In the titration study, KaolinTEG and FFTEG displayed a continuous dose-response association and RapidTEG also displayed a dose-dependent response but only for higher levels of tPA, thus yielding a smaller "dose-sensitive range" compared to KaolinTEG and FFTEG.
CONCLUSION: This pilot study demonstrated that KaolinTEG, RapidTEG, and FFTEG all were able to detect lysis at 1.8 nmol/L tPA but with a difference in sensitivity. Furthermore, KaolinTEG and FFTEG showed a continuous dose dependence related to the tPA concentration, whereas RapidTEG only detected lysis at higher tPA concentrations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22297558     DOI: 10.1177/1076029611434527

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  9 in total

Review 1.  Fibrinolysis in trauma: a review.

Authors:  M J Madurska; K A Sachse; J O Jansen; T E Rasmussen; J J Morrison
Journal:  Eur J Trauma Emerg Surg       Date:  2017-09-16       Impact factor: 3.693

2.  Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid.

Authors:  Daniel Glenn Kindell; Rick Wayne Keck; Jerzy Jankun
Journal:  Exp Ther Med       Date:  2015-04-01       Impact factor: 2.447

3.  Hypercoagulability in response to elevated body temperature and central hypovolemia.

Authors:  Martin A S Meyer; Sisse R Ostrowski; Anders Overgaard; Matthew S Ganio; Niels H Secher; Craig G Crandall; Pär I Johansson
Journal:  J Surg Res       Date:  2013-06-29       Impact factor: 2.192

4.  Kaolin activation of recalcified citrated whole blood in a point-of-care viscoelastic coagulation test.

Authors:  Amy M Molitoris; Armelle M deLaforcade; Alexandra Pfaff; Elizabeth A Rozanski
Journal:  Can J Vet Res       Date:  2022-10       Impact factor: 0.897

5.  Fibrinolysis for intermediate-risk pulmonary embolism.

Authors:  Eduardo Gonzalez; Hunter B Moore; Ernest E Moore
Journal:  N Engl J Med       Date:  2014-08-07       Impact factor: 91.245

6.  Iodinated contrast does not alter clotting dynamics in acute ischemic stroke as measured by thromboelastography.

Authors:  Mark M McDonald; Joancy M Archeval-Lao; Chunyan Cai; Hui Peng; Navdeep Sangha; Stephanie A Parker; Jeremy Wetzel; Stephen A Riney; Matt F Cherches; Greer J Guthrie; Tiffany C Roper; Jorge F Kawano-Castillo; Renga Pandurengan; Mohammad H Rahbar; James C Grotta
Journal:  Stroke       Date:  2013-12-26       Impact factor: 7.914

7.  Assays of different aspects of haemostasis - what do they measure?

Authors:  Nahreen Tynngård; Tomas L Lindahl; Sofia Ramström
Journal:  Thromb J       Date:  2015-02-05

8.  Development and validation of a high throughput whole blood thrombolysis plate assay.

Authors:  T Bonnard; L S Law; Z Tennant; C E Hagemeyer
Journal:  Sci Rep       Date:  2017-05-24       Impact factor: 4.379

Review 9.  Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).

Authors:  Marzena Wyganowska-Świątkowska; Mateusz Tarnowski; Daniel Murtagh; Ewa Skrzypczak-Jankun; Jerzy Jankun
Journal:  Int J Mol Med       Date:  2018-11-07       Impact factor: 4.101

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.